Key facts
- This page summarizes Christopher Astle's Form 3 filing for Zymeworks Inc..
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2022, 20:20.
Christopher Astle - 24 Feb 2022 Form 3 Insider Report for Zymeworks Inc.
- Reporting relationship
- SVP & Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 24 Feb 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 04 Mar 2022, 20:20:57 UTC
- Next SEC filing
- 11 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Dex, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Astle filed Form 3 for Zymeworks Inc. on 04 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZYME
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 670
- Date
- 24 Feb 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZYME
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 17,250
- Exercise price
- $29.81
- Footnotes
- F1, F2
ZYME
holding
Derivative
Restricted Stock Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 3,100
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Stock options vest as follows: (i) 25% on May 17, 2022 (the first anniversary of grant date) and (ii) remainder in 36 equal monthly installments on last day of each month following first anniversary of grant date.
Footnote F2
The exercise price of the stock option was converted from CAD36.01 using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
Footnote F3
The restricted stock units vest in two equal annual installments beginning on December 10, 2022.
Footnote F4
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney